Method of treating acute coronary syndrome
AssigneesAlfred Health, Peking University Third Hospital
InventorsAnthony Dart, Wei Gao
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for prognosing ACS in a subject, the method comprising determining plasma MIF and Nt-proBNP (or BNP) concentrations in a sample from the subject, diagnosing ACS when the subject plasma concentrations are greater than a reference MIF and Nt-proBNP (or BNP) plasma concentration, and prognosing the magnitude of ACS from the subject plasma MIF and Nt-proBNP (or BNP) concentrations. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of prognosing ACS.
Claims14
A method of treating acute coronary syndrome (ACS) in a subject, the method comprising:
- determining the concentration of:
- (a) macrophage migration inhibitory factor (MIF), and
- (b) N-terminal prohormone of brain natriuretic peptide (Nt-proBNP), or brain natriuretic peptide (BNP),
- in a sample from the subject, wherein the sample is blood, plasma or serum,
- comparing the concentration of MIF to a reference MIF concentration, wherein the reference MIF concentration is at least 70 ng/ml,
- comparing the concentration of Nt-proBNP (or BNP) to a reference Nt-proBNP (or BNP) concentration, wherein the reference Nt-proBNP (or BNP) concentration is at least 700 pg/mL, and
- performing percutaneous coronary intervention (PCI) and/or fibrinolysis on the subject when the concentrations of MIF and Nt-proBNP (or BNP) from the sample are equal to or higher than the reference concentrations of MIF and Nt-proBNP (or BNP),
- thereby treating the subject having ACS.
Dependencies are inferred from the claim text.